Get the Stockscreener App
2.18
8.79%
-0.21
Pre-market:
2.21
0.03
+1.38%
Icecure Medical Ltd stock is traded at $2.18, with a volume of 129.78K.
It is down -8.79% in the last 24 hours and down -68.38% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$2.39
Open:
$2.44
24h Volume:
129.78K
Relative Volume:
2.77
Market Cap:
$6.12M
Revenue:
$3.57M
Net Income/Loss:
$-15.74M
P/E Ratio:
-0.3138
EPS:
-6.9481
Net Cash Flow:
$-15.77M
1W Performance:
-40.11%
1M Performance:
-68.38%
6M Performance:
-88.65%
1Y Performance:
-92.52%
1-Day Range:
$2.17
$2.49
1-Week Range:
$2.17
$3.56
52-Week Range:
$2.17
$42.00
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
2.18 | 6.12M | 3.57M | -15.74M | -15.77M | -6.9481 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Icecure Medical Ltd Stock (ICCM) Latest News
IceCure Medical (ICCM) Falls Over 11%: Key Support Levels Tested After Sharp DeclineCall Resistance - newsline.com
Icecure Medical Analyst Ratings and Price Targets | NASDAQ:ICCM - Benzinga
IceCure Medical to boost share price with 1-for-30 reverse split to regain NASDAQ compliance - MSN
IceCure Medical announces reverse share split - Medical Buyer
IceCure Medical (ICCM) Announces 1-for-30 Reverse Stock Split to Meet Nasdaq Requirements - GuruFocus
IceCure Medical: Split Part of Co's Proactive Efforts to Regain Compliance With Nasdaq $1 Minimum Bid Price Requirement and Support Co's Broader Cap Markets Strategy >ICCM - Moomoo
IceCure Medical (ICCM) Announces 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing - GuruFocus
IceCure Medical Announces 1-for-30 Reverse Share Split to Maintain Nasdaq Listing - geneonline.com
IceCure Stock Drops Before The Bell As Nasdaq’s $1 Clock Ticks - Bez Kabli
IceCure Medical (NASDAQ: ICCM) implements 1-for-30 reverse share split for Nasdaq - Stock Titan
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance - PR Newswire
IceCure Medical Enacts 1-for-30 Reverse Share Split to Bolster Nasdaq Compliance - TipRanks
Why Has IceCure Medical's Stock Price Collapsed - Kavout
Number of shareholders of IceCure Medical Ltd. – BOATS:ICCM - TradingView
IceCure Medical (ICCM) Retreats Toward Support After 4% DeclineFair Value Gap - newsline.com
IceCure Medical (ICCM) Edges Higher as Stock Tests Key Resistance Near $0.24Advance Decline Volume - The Legal Advocate
Icecure Medical Earnings Call Highlights Growth Momentum - The Globe and Mail
Icecure Medical Ltd (ICCM) Q1 2026 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Icecure Medical Ltd (ICCM) Q1 2026 Earnings Call Highlights: Rob - GuruFocus
IceCure Medical presents positive ProSense cryoablation data - grafa.com
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for - GuruFocus
IceCure Showcases Strong ProSense® Cryoablation Data and Surge in Clinical Interest at ECIO 2026 - TipRanks
IceCure Medical (ICCM) highlights kidney and breast cryoablation data at ECIO 2026 - Stock Titan
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked - PR Newswire
[Form 4] IceCure Medical Ltd. Insider Trading Activity - Stock Titan
IceCure Medical : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
IceCure Medical (ICCM) CFO reports 400,000 RSUs equity grant - Stock Titan
IceCure Medical Ltd. (ICCM) reports Q1 loss, lags revenue estimates - MSN
IceCure Medical Ltd.Ordinary Shares (NQ: ICCM - The Chronicle-Journal
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Cuts Target Price to $1 - Moomoo
ICCM Maintained by Maxim Group -- Price Target Lowered to $1.00 - GuruFocus
IceCure Medical Wins Nasdaq Extension to Restore Minimum Bid Compliance - The Globe and Mail
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - The Malaysian Reserve
Icecure granted 180-day extension by Nasdaq to regain compliance with minimum bid requirement - marketscreener.com
IceCure Medical (ICCM) wins new 180-day window to meet Nasdaq $1 bid - Stock Titan
IceCure Medical Ltd (NASDAQ:ICCM) Q1 2026 Earnings Call Transcript - Insider Monkey
IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America - StreetInsider
ICECURE MEDICAL ($ICCM) Releases Q1 2026 Earnings - Moomoo
[424B5] IceCure Medical Ltd. Prospectus Supplement (Debt Securities) - Stock Titan
IceCure Medical Sets Up At-the-Market Equity Program With A.G.P./Alliance Global Partners - TipRanks
[6-K] IceCure Medical Ltd. Current Report (Foreign Issuer) | ICCM SEC FilingForm 6-K - Stock Titan
ICCM: Strong Q1 Revenue Growth Signals Positive Market Momentum - GuruFocus
IceCure (ICCM) Q1 2026 Earnings Transcript - AOL.com
IceCure Reports First Quarter 2026 Financial Results: ProSense® - GuruFocus
ICCM: Q1 2026 revenue up 26% year-over-year, driven by U.S. growth and post-FDA commercial momentum - TradingView
ICCM: Q1 2026 saw 26% revenue growth and accelerating U.S. adoption following FDA clearance - TradingView
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):